NEWS: Encouraging data released for EZH2 inhibitor study for malignant mesothelioma

One of this year’s American Society for Clinical Oncology (ASCO) updates in mesothelioma included the release of the first results for the Phase 2 Study of the EZH2 inhibitor, tazemetostat, for malignant mesothelioma, presented by the chair of the board of the Mesothelioma Applied Research Foundation (Meso Foundation), Marjorie Zauderer, MD.
This study enrolled 61 BAP1 […]

DREAM Trial: Optimistic results from the first 31 patients

Earlier this month, during the most recent meeting of the American Society of Clinical Oncology (ASCO), first results from a new study are bound to bring hope to the mesothelioma community.
The aptly named DREAM study coming out of Australia is one of the first of its kind in mesothelioma, and so far, its results look […]

JUST PUBLISHED: New report outlining progress in mesothelioma treatment in 2017

A new article reviewing progress and advances that occurred in 2017 in the management of pleural mesothelioma was just published in the May 2018 issue of the Journal of Thoracic Oncology.
The publication is the result of collaboration among mesothelioma experts from around the world, including several current and former members of the Mesothelioma Applied Research […]

Congress funds congressionally directed DOD funding for FY18 with $80 million

We are excited to report that Congress has funded the congressionally directed Department of Defense (DoD) funding for Fiscal Year 2018 (FY18) with $80 million to support innovative, high-impact cancer research. This is a major increase from last year’s $60 million, $50 million the year before, and $25 million two years prior. The upward trend, in […]